A

The study concluded that upfront KIT mutation testing improves response prediction (higher CR/PR rates in exon 11 mutants) and helps tailor timing of surgery, indicating that mutation analysis can indeed guide (“be a pathfinder”) neoadjuvant imatinib therapy in locally advanced GISTs [Ramaswamy et al., 2016, PMID 27217036].